Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.32 EUR -0.45% Market Closed
Market Cap: 157.4m EUR

EV/EBITDA
Enterprise Value to EBITDA

-2.3
Current
-3.5
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.3
=
Enterprise Value
152.4m EUR
/
EBITDA
-66.8m EUR
EBITDA Growth EV/EBITDA to Growth
FR
Nanobiotix SA
PAR:NANO
Average EV/EBITDA: 15.3
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 873.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -623.6 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-3.1
2-Years Forward
EV/EBITDA
5.8
3-Years Forward
EV/EBITDA
36.4